Sagility India Limited
(Formerly Sagility India Private Limited)
Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, 
Bommanahalli, Bengaluru – 560068 Karnataka India
Corporate Identity Number: L72900KA2021PLC150054
Tel. No.: 080-71251500, Website: www.SagilityHealth.com
Date: May 14, 2025
To, 
The Manager 
Listing Department 
National Stock Exchange (NSE) 
Exchange Plaza, 5th Floor 
Plot No. C/1, G-Block 
Bandra-Kurla Complex 
Bandra (E), Mumbai - 400 051 
Symbol: SAGILITY
To,
The Manager 
Listing Department 
Bombay Stock Exchange (BSE) 
Phiroze Jeejeebhoy Towers 
Dalal Street Mumbai - 400 001 
Scrip Code:544282
Dear Sir/Ma’am, 
Subject: Submission of Investor Presentation to be made to investors on May 15, 2025, pursuant 
to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015
In continuation to our letter dated May 09, 2025, we are enclosing herewith the presentation to be shared 
with investors regarding the audited financial results of the Company for quarter and year ended 31st 
March 2025 at 8:30AM (IST).
The details are also being made available on the Company’s website https://sagilityhealth.com/ 
This is for your kind information and record.
Thanking You, 
For Sagility India Limited 
Satishkumar Sakharayapattana Seetharamaiah   
Company Secretary & Compliance Officer   
M. No: A16008
Encl: a/a

Investor Deck – FY25
May 15, 2025

Safe Harbour
Certain statements in this release concerning Sagility’ future growth prospects may be seen as forwardlooking statements, which involve a number of risks and uncertainties that could cause the actuals to differ 
materially from such statements. Sagility does not undertake to update any such statement that may have 
been made from time to time by or on behalf of the company..
2

Key Highlights
► FY25 Revenue at ₹55,699 million, grew by ₹8,164 million Y-o-Y 
(corresponding to 17.2% growth Y-o-Y and 14.9% at constant currency. 
► Adjusted EBITDA (excl Other Income) at ₹14,685 million, grew by ₹3,249 
million Y-o-Y (corresponding to 28.4% growth Y-o-Y )
► Adjusted PAT at ₹8.107 million, grew by ₹ 2,211 million Y-o-Y (corresponding 
to 37.5% growth Y-o-Y )
► Revenue in Q4 at ₹ 15,685 million grew by ₹2,853 million Y-o-Y (corresponding 
to 22.2% growth Y-o-Y and 17.7% at constant currency. 
► Adjusted EBITDA (excl Other Income) at ₹4,042 million, grew by ₹899 million Yo-Y (corresponding to 28.6% growth Y-o-Y )
► Adjusted PAT at ₹2,398 million, grew by ₹747 million Y-o-Y (corresponding to 
45.2% growth Y-o-Y )
► FY25 concluded with robust year-on-year growth, largely fueled by our tenured existing clients and logos won over the last couple of years. Total Q-o-Q growth of 
7.9% in INR and 5.7% in constant currency was fueled by acquisition of Broadpath in Q4.
► Together with tech- and transformation-led services—powered by automation, analytics, and GenAI, and our consulting services, we are gaining strong traction with 
clients, further enhancing our reputation as a trusted strategic and advisory partner.
► Recent acquisition of BroadPath has the potential to unlock additional opportunities in several mid-market clients of Broadpath ; targeted cross-sell initiatives planned 
for FY26
► Operations remain robust, driven by strong performance across key metrics
► People: Global headcount stands at 39,409 as of Mar 2024.
► 4,365 employees added during FY25 (12.5% Y-o-Y growth in headcount); Attrition at 27.5%*
► Recognitions: Major Contender in the Everest Group Payment Integrity Solutions PEAK Matrix® Assessment 2025; Major Contender in Healthcare Payer Business 
Process as a Service (BPaaS) – Solutions PEAK Matrix® Assessment 2024
Key Business Highlights
* Voluntary attrition considering employees who were employees for more than 90 days (%) on an annualized basis exclude BroadPath
FY25 Highlights Q4 FY25 Highlights
3

KPIs
*considering employees who were employees for more than 90 days (%) on an annualized basis. **FY attrition rate exclude BroadPath 4
KPI Q4'25 Q3'25 Q4'24 YoY% FY'25 FY'24 YoY%
Revenue from Operation (in INR Million) 15,685 14,531 12,832 22.2% 55,699 47,536 17.2%
Revenue by Vertical Split
By Payer % 89.7% 89.3% 90.8% 89.4% 90.3%
By Provider % 10.3% 10.7% 9.2% 10.6% 9.7%
Growth in revenue from operation (%) 22.2% 15.3% 17.2% 12.7%
Adjusted EBITDA (in INR Million) 4,143 4,567 3,188 30.0% 15,248 11,715 30.2%
Adjusted EBITDA % 26.4% 31.4% 24.8% 27.4% 24.6%
Adjusted PAT (in INR Million) 2,398 2,626 1,651 45.2% 8,107 5,896 37.5%
Adjusted PAT % 15.3% 18.1% 12.9% 14.6% 12.4%
Total Number of Employees 39,409 39,595 35,044 12.5% 39,409 35,044 12.5%
Voluntary attrition rate* (%) 32.5% 21.8% 30.4% 27.5% 27.2%**

Annual KPI’s
5
KPI FY'25 FY'24 FY’23
Number of Client groups*
Active 75 44 35
Number of new client addition (Gross) 38 13 7
Client groups contribution to revenues
Top 3 Client % 66.2% 68.3% 72.4%
Top 5 Client % 77.9% 79.2% 80.6%
Top 10 Client % 90.5% 91.4% 90.7%
Number of Million-dollar client groups
Number of clients contributing more than US$20 million 7 5 4
Number of clients contributing to US$5 - US$20 million 6 7 7
Number of clients contributing to US$1 - US$5 million 12 12 12
Number of clients contributing less than US$1 million 50 20 12
Delivery sites
Number of delivery sites 33 30 27
New site addition (Gross) 10 4 2
* Client groups comprise client entities together with their affiliates. 

Financial Highlights

Highlights
FY25 Financial Highlights
► FY25 revenue stood at ₹55,699 Million ($658.3 M)
► 17.2% growth Y-o-Y (14.9% at constant currency )
► Adjusted EBITDA (excl OI) at ₹14,685 Million ($173.6 M) 
► Adjusted EBITDA Margin : 26.4%
► 28.4% growth Y-o-Y
► Adjusted PAT at ₹8,107 Million ($95.8 M)
► Adjusted PAT Margin: 14.6%
► 37.5% growth Y-o-Y;
► OCF ₹12,141 Million ($ 143.5 M)
► 89.7% of EBITDA
► Q4’25 revenue stood at ₹15,685 Million ($181.8 M)
► 22.2% growth Y-o-Y (17.7% at constant currency )
► 7.9% growth Q-o-Q (5.7% at constant currency)
► Adjusted EBITDA (excl OI) at ₹4,042 Million ($46.8 M)
► Adjusted EBITDA Margin : 25.8%
► 28.6% growth Y-o-Y; 
► Adjusted PAT at ₹2,398 Million ($27.8 M)
► Adjusted PAT Margin : 15.3 %
► 45.2% growth Y-o-Y
► OCF ₹3,009 Million ($34.8 M)
► 78.5% of EBITDA
Strong FY25 Performance
Q4 FY25 Financial Highlights
7

₹11.2 ₹10.9
₹12.6 ₹12.8
12.8% 11.5% 12.4% 12.9%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
₹9.0
₹10.0
₹11.0
₹12.0
₹13.0
₹14.0
₹15.0
Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24
Revenue INR B Adjusted PAT %
Quarter wise performance
33.5
* Q4 FY 25 Headcount includes BroadPath Headcount of 1,083 (acquired in Q4 FY25) 
FY 24
36.5 36.6 35.0
35.8 38.3 39.6
Headcount 
(‘000)
Headcount 
(‘000)
₹12.2
₹13.3
₹14.5
₹15.7
11.8% 12.3%
18.1%
15.3%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
₹9.0
₹10.0
₹11.0
₹12.0
₹13.0
₹14.0
₹15.0
₹16.0
₹17.0
Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25
Revenue INR B Adjusted PAT %
FY 25
39.4*

Financial performance snapshot – Long Term
Revenue 
(INR Million) 
FY24 YoY% FY25 YoY%
12.7% 17.2%
Adjusted EBITDA * 
(INR Million)
FY24 YoY% FY25 YoY%
11.3% 28.4%
Adjusted PAT
(INR Million)
FY24 YoY% FY25 YoY%
29.4% 37.5%
Revenue ($M) 
FY24 YoY% FY25 YoY%
10.5% 14.9%
Adjusted EBITDA* 
($M)
FY24 YoY% FY25 YoY%
9.2% 25.9%
Adjusted PAT
($M)
FY24 YoY% FY25 YoY%
27.0% 34.8%
9
₹42,184
₹47,536
₹55,699
FY'23 FY'24 FY'25
₹10,272 ₹11,436
₹14,685
FY'23 FY'24 FY'25
₹4,556
₹5,896
₹8,107
FY'23 FY'24 FY'25
$518.2 $572.9
$658.3
FY'23 FY'24 FY'25
$126.2 $137.8
$173.6
FY'23 FY'24 FY'25
$56.0
$71.1
$95.8
FY'23 FY'24 FY'25
*Adjusted EBITDA excluding other income

Financial performance snapshot – Q4 FY25
Revenue 
(INR Million) 
Y-o-Y Q-o-Q
22.2% 7.9%
Adjusted EBITDA* 
(INR Million)
Y-o-Y Q-o-Q
28.6% -2.1%
Adjusted PAT
(INR Million)
Y-o-Y Q-o-Q
45.2% -8.7%
Revenue ($M) 
Y-o-Y Q-o-Q
17.7% 5.7%
Adjusted EBITDA* 
($M)
Y-o-Y Q-o-Q
23.8% -4.2%
Adjusted PAT
($M)
Y-o-Y Q-o-Q
40.1% -10.6%
10
₹12,832
₹14,531 ₹15,685
Q4'24 Q3'25 Q4'25
₹3,143
₹4,127 ₹4,042
Q4'24 Q3'25 Q4'25
₹1,651
₹2,626
₹2,398
Q4'24 Q3'25 Q4'25
$154.4
$172.0
$181.8
Q4'24 Q3'25 Q4'25
$37.8
$48.9 $46.8
Q4'24 Q3'25 Q4'25
$19.9
$31.1
$27.8
Q4'24 Q3'25 Q4'25
*Adjusted EBITDA excluding other income

Financial Indicators
Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares
Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities)
Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent. Borrowing doesn’t include accrued interest 11
1.06 
1.38 
1.76 
FY'23 FY'24 FY'25
Adjusted EPS (in INR)
41.6%
47.0%
54.9%
FY'23 FY'24 FY'25
Adjusted ROCE %
82.0% 87.2% 89.7%
68.2% 70.8%
80.5%
FY'23 FY'24 FY'25
Cash Conversion (%)
OCF % FCF %
₹22,863 ₹21,678
₹10,432
2.19x
1.85x
0.68x
 -
 0.50
 1.00
 1.50
 2.00
 2.50
₹0
₹5,000
₹10,000
₹15,000
₹20,000
₹25,000
FY'23 FY'24 FY'25
Net Debt
Net Debt (in INR Million) Net Debt to Adjusted EBITDA

Q4 & FY25 Consolidated Financials 
Amt in INR M
Particulars Q4 FY25 Q3 FY25 Q4 FY24 YoY% QoQ% FY25 FY24 YoY%
Revenue from Operation 15,685 14,531 12,832 22.2% 7.9% 55,699 47,536 17.2%
Other Income 101 440 46 563 279 
Employee benefits expense 9,741 8,620 7,995 34,989 29,376
Other expenses 2,212 1,988 1,764 7,731 7,278 
Reported EBITDA 3,832 4,362 3,119 22.9% -12.2% 13,542 11,160 21.3%
Adjusted EBITDA 4,143 4,567 3,188 30.0% -9.3% 15,248 11,715 30.2%
Adjusted EBITDA % 26.4% 31.4% 24.8% 27.4% 24.6%
Adjusted EBITDA excl. other income 4,042 4,127 3,143 28.6% -2.1% 14,685 11,436 28.4%
Adjusted EBITDA excl. other income % 25.8% 28.4% 24.5% 26.4% 24.1%
Finance costs 298 302 429 1,271 1,851
Depreciation and amortisation expenses 1,143 1,162 1,760 4,669 6,892
Profit Before Tax 2,390 2,898 929 157.3% -17.5% 7,602 2,417 214.6%
Tax Expenses 564 729 127 2,211 134
Reported Profit After Tax 1,826 2,169 802 127.6% -15.8% 5,391 2,283 136.2%
EPS 0.39 0.46 0.19 108.5% -15.8% 1.17 0.53 119.3%
Adjusted PAT 2,398 2,626 1,651 45.2% -8.7% 8,107 5,896 37.5%
Adjusted PAT % 15.3% 18.1% 12.9% 14.6% 12.4%
Adjusted EPS (Basic and Diluted) (Rs) 0.51 0.56 0.39 33.0% -8.7% 1.76 1.38 27.7% 12
❖ Q4’25 Organic Revenue at INR 
14,929 Mn (YoY% 16.3% and 
QoQ% 2.7%)
❖ FY’25 Organic Revenue at INR 
54,943 Mn (YoY% 15.6%)
❖ Q4 Adj. EBITDA margin (excl. OI) is 
lower than Q3 due to (a) Change 
in revenue mix as BroadPath is 
onshore (b) Salary hikes made 
effective from Jan 25
❖ Dip in Q4 Reported EBITDA 
margins due to above and lower 
other income and earnout for 
BroadPath
❖ Finance cost include interest cost 
on long-term borrowing from 
promoter and interest expenses on 
lease liabilities

Adjustments on EBITDA and PAT
Adj EBITDA Bridge: Q4 FY25 Adj EBITDA Bridge: FY25
Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax
Adj B - Share based payment awards ( non cash expenses for the company and not tax deductible)
Adj C - Intangible assets Amortization is amortization of intangible assets acquired pursuant to carveout of healthcare business from the seller
Adj PAT Bridge: Q4 FY25 Adj PAT Bridge: FY25
INR Million
INR Million INR Million
INR Million
13
₹3,832 ₹207 ₹104 ₹4,143
Reported EBITDA Adj A Adj B Adjusted EBITDA
₹13,542 ₹571
₹1,134 ₹15,248
Reported EBITDA Adj A Adj B Adjusted EBITDA
₹1,826
₹151 ₹104
₹317 ₹2,398
Reported PAT Adj A Adj B Adj C Adjusted PAT
₹5,391
₹418
₹1,134
₹1,163 ₹8,107
Reported PAT Adj A Adj B Adj C Adjusted PAT

Go Forward Positions
• Numbers are based on the current visibility of management and are subject to change. Factors such as new loans, acquisitions, foreign exchange rate or changes in our sharebased payment award plan could impact the final figures
• Intangible Amortisation include amortization of intangible assets acquired pursuant to business combinations (includes DCI, Birch and BroadPath)
14
Amt in INR M
Particulars FY'25 FY'26 FY'27 FY'28 FY'29
Closing Debt position 8,020 5,670 
Debt Repayment 2,490 2,350 5,670 
Interest Payment 751 535 285 
Share based Payment awards 1,134 250 146 78 40 
Earnouts Cost - DCI / Birch/ BroadPath 571 494 5
Intangibles Amortisation 1,588 1,795 1,785 1,771 1,698 

Balance Sheet as on 31st Mar’25
15
Amt in INR M
Particulars Mar’25 Mar'24
Property, plant and equipment 3,699 3,832
Capital-work-in-progress 0 57
Right-of-use assets 5,521 5,665
Goodwill 60,390 57,096
Other intangible assets 20,362 20,078
Trade receivables and Unbilled 12,668 11,813
Cash and cash equivalents 3,438 3,441
Deferred tax assets (net) 1,337 1,354
Other Assets 3,091 3,305
Total Assets 110,507 106,642
Equity 83,361 64,431
Borrowings 8,170 19,335
Lease liabilities 5,850 5,982
Trade payables 2,136 2,593
Other financial liabilities 3,059 6,587
Deferred tax liabilities (net) 4,279 4,710
Other Liabilities 3,653 3,004
Total Liabilities 110,507 106,642
❖ Increase in Goodwill and Intangible driven 
by BroadPath acquisition
❖ Intangibles of $16.5M created as a result of 
BroadPath acquisition
❖ DSO (excl. BroadPath) of 79 days in Mar’25 
against 85 days in Mar’24.
❖ Borrowings (Promoter Debt) reduction due 
to conversion of loan into equity (in May’24) 
and repayment of debt.
❖ Reduction in Other financial liabilities 
pertains to pending purchase consideration 
paid towards for healthcare business 
carveout in Jan 22

Cash Flow – FY25 
16
Amt in INR M
Particulars FY’25 FY'24
Profit before tax for the period/ year 7,602 2,417
Adjustment for Non-Operating and Non-Cash items 6,982 8,693
Adjustment for working capital (710) (114)
Income taxes paid (net of refunds) (1,734) (1,263)
Net cash flows generated from operating activities (A) - OCF 12,141 9,733
Addition to Fixed Assets (1,244) (1,827)
Free Cash flow (FCF) 10,896 7,905
Cash paid for M&A (BroadPath) (4,825) (3,010)
Pending Purchase consideration paid for healthcare business carveout (3,756)
Others* 184 147
Net cash flows (used in) investing activities (B) (9,642) (4,691)
Capital infused by promoter 3,708 0
IPO expense reimbursed 72 (72)
Repayment of borrowings and lease liabilities (5,021) (5,546)
Interest paid on borrowings and lease liabilities (1,320) (1,896)
Net cash flows (used in) financing activities (C) (2,561) (7,513)
Net increase/ (decrease) in cash and cash equivalents (A+B+C) (62) (2,471)
Cash and cash equivalents at the beginning of the year/period 3,441 5,853
Effect of movement in exchange rates on cash and cash equivalents 58 60
Cash and cash equivalents at the end of the year/ period 3,438 3,441
Net cash flows generated from operating activities % (OCF on Reported EBITDA) 89.7% 87.2%
Free Cash flow % (FCF on EBITDA) 80.5% 70.8%
❖ Non-Cash/Non-Operating Items 
includes Depreciation, Interest 
expenses, SAR, Unrealized Fx loss 
and Interest income
❖ Others include Proceeds from sale of 
fixed assets, Interest income and 
Proceeds from maturity of derivative 
assets/liabilities, (net)

Thank You